What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Internal medicine, Surgery, Gastroenterology, Cancer research and Lymphoma are his primary areas of study.
Internal medicine is closely attributed to Oncology in his work.
His Gastroenterology study which covers Survival analysis that intersects with Interleukin.
The Cancer research study combines topics in areas such as Immunology, Cytokine, Apoptosis, Programmed cell death and Signal transduction.
In his study, which falls under the umbrella issue of Lymphoma, CD40 is strongly linked to Chronic lymphocytic leukemia.
His Transplantation research incorporates elements of Preparative Regimen, Nivolumab, Neutropenia and Hodgkin's lymphoma.
His most cited work include:
- Guidelines for the use and interpretation of assays for monitoring autophagy (3242 citations)
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas (1008 citations)
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma (985 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Lymphoma, Oncology, Cancer research and Surgery.
His research in Internal medicine tackles topics such as Gastroenterology which are related to areas like Non-Hodgkin's lymphoma.
Immunology and Pathology are inextricably linked to his Lymphoma research.
His work deals with themes such as Clinical trial, Neutropenia, Refractory and Hodgkin lymphoma, which intersect with Oncology.
His research integrates issues of Apoptosis, Protein kinase B, PI3K/AKT/mTOR pathway and Programmed cell death in his study of Cancer research.
His Rituximab research is multidisciplinary, incorporating perspectives in Progression-free survival, Vincristine, Cyclophosphamide, Follicular lymphoma and Prednisone.
He most often published in these fields:
- Internal medicine (59.03%)
- Lymphoma (35.48%)
- Oncology (34.07%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (59.03%)
- Oncology (34.07%)
- Lymphoma (35.48%)
In recent papers he was focusing on the following fields of study:
Anas Younes focuses on Internal medicine, Oncology, Lymphoma, Cancer research and Rituximab.
His study in Brentuximab vedotin, Follicular lymphoma, Chemotherapy, Chemotherapy regimen and ABVD falls under the purview of Internal medicine.
His work in Oncology covers topics such as Nivolumab which are related to areas like Hematopoietic stem cell transplantation.
His Lymphoma study combines topics from a wide range of disciplines, such as Venetoclax and Cancer.
His study looks at the relationship between Cancer research and topics such as Hodgkin lymphoma, which overlap with Clinical trial.
His Rituximab study integrates concerns from other disciplines, such as Progression-free survival, Gastroenterology, Prednisone and Vincristine, Cyclophosphamide.
Between 2016 and 2021, his most popular works were:
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists (521 citations)
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma (290 citations)
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. (258 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His main research concerns Internal medicine, Oncology, Lymphoma, Cancer research and Brentuximab vedotin.
Anas Younes combines Internal medicine and Population in his research.
His Oncology research is multidisciplinary, incorporating elements of Classical Hodgkin lymphoma, Clinical trial, Refractory, Mantle cell lymphoma and Advanced stage.
His biological study spans a wide range of topics, including Cancer and Histone deacetylase inhibitor.
His Cancer research study incorporates themes from Bromodomain, Immune system, Diffuse large B-cell lymphoma, MHC class I and Bruton's tyrosine kinase.
His Brentuximab vedotin research is multidisciplinary, relying on both Chlorambucil and ABVD.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
